Francois Valencony
Chief Investment & Business Officer @ General Inception
Boston, United States
Francois Valencony is a Series C investor at General Inception in Boston focused on Health Care and Life Science. Francois Valencony - Managing Partner & Executive Officer @ Mérieux Equity Partners
- Total investments:
- 16
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Francois Valencony invests in
Health CareLife ScienceTherapeuticsBiotechnologySoftware
Stages Francois Valencony invests in
Series CSeries BSeries DFunding RoundPrivate Equity
Countries Francois Valencony invests in
United StatesLuxembourg
Investment Focus
Industry
- Health Care 3 (19%)
- Life Science 2 (13%)
- Therapeutics 2 (13%)
- Biotechnology 2 (13%)
- Software 1 (6%)
Stage
- Series C 2 (13%)
- Series B 1 (6%)
- Series D 1 (6%)
- Funding Round 1 (6%)
- Private Equity 1 (6%)
Country
- United States 2 (13%)
- Luxembourg 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Inscripta
|
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $20M / Series C / Apr 04, 2019 | |
|
Inscripta
|
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $20M / Series C / Apr 04, 2019 | |
|
Inscripta
|
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $30M / Series C / Dec 19, 2018 | |
|
Inscripta
|
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $30M / Series C / Dec 19, 2018 | |
|
Inscripta
|
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $55.5M / Series C / Feb 28, 2018 | |
|
Inscripta
|
Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $55.5M / Series C / Feb 28, 2018 | |
Proclara Biosciences
|
NeuroPhage Pharmaceuticals, Inc. is a biotechnology company, develops disease-modifying therapies for the treatment of neurodegenerative diseases. The company develops a protein disaggregation platform for the treatment of Alzheimer’s, Parkinson’s, Huntington’s, amyotrophic lateral and multiple sclerosis, and other neurodegenerative diseases. Itoffers NPT001, a drug candidate for Alzheimer’s disease to disaggregate existing plaque in preclinical animal models. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. | $17M / Series D / Mar 25, 2014 | |
Lavorel Medicare
|
Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory,through 50 agencies. | Jun 20, 2013 | |
|
Lavorel Medicare
|
Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory,through 50 agencies. | Jun 20, 2013 | |
|
Lavorel Medicare
|
Lavorel Medicare is a service provider specialized in nursing care at home or in special care units. Its German subsidiary Bonitas GmbH, which employs about 3,000 people, specializes in medical support to disabled patients with chronic diseases or genetic pathologies .Bonitas GmbH supports over 2,000 patients throughout the German territory,through 50 agencies. | Private Equity / May 27, 2013 | |
| See all 16 investments → | |||
Co-Investors
About General Inception
General Inception is an institutional co-founder for science-based companies bringing specialized expertise, operational resources and capital to innovation.
General Inception Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Francois Valencony
Chief Investment & Business Officer
|
|||
Jeff Rieger
Fractional Executive
|
|||
Paul Conley
CEO & Co-founder
|
|||
Soumya Ray
Fraction Executive, Advisor and Company Builder
|
|||
Venkat Reddy
CSO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
SaaS Investors
99,274 investors
Software Investors
50,021 investors
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Life Science Investors
6,823 investors
SaaS VC Funds
61,208 investors
Software VC Funds
31,919 investors
Health Care VC Funds
32,370 investors
FAQ
What does Francois Valencony invest in?
Francois Valencony invests primarily in Health Care, Life Science and Therapeutics startups, most often at Series C and Series B stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Francois Valencony last invest?
The most recent investment recorded for Francois Valencony closed in Apr 2019. Shizune tracks 16 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
